[Primary gastrointestinal follicular lymphoma of the small intestine with massive hemorrhage: a report of three cases]

Rinsho Ketsueki. 2016 Mar;57(3):353-8. doi: 10.11406/rinketsu.57.353.
[Article in Japanese]

Abstract

Primary gastrointestinal follicular lymphoma (FL) has an indolent clinical presentation and many of cases are diagnosed incidentally during routine endoscopic examinations. Herein, we present 3 cases with FL of the small intestine developed massive intestinal hemorrhage that necessitated blood transfusion. In all three patients, upper and lower endoscopic examinations failed to detect the bleeding sites. Eventually, video capsule endoscopies identified ulcerative lesions in the jejunum and biopsies using single- or double-balloon endoscopy confirmed the FL diagnosis in our three cases. The respective clinical stages according to the Lugano system were I, II-1 and II-1. PET-CT did not play a significant role in identifying the gastrointestinal lesions. Two patients received rituximab monotherapy and achieved a complete response. The other remains under observation after termination of antiplatelet drug therapy. Generally, the macroscopic appearance of multiple whitish nodules and the absence of symptoms represent the typical clinical picture of gastrointestinal FL. However, this study demonstrates that patients with ulcerative lesions may be at risk for massive bleeding. Further discussion is required to determine the optimal indications for total endoscopic examination of the small intestine.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use
  • Duodenal Neoplasms / complications
  • Duodenal Neoplasms / drug therapy*
  • Duodenal Neoplasms / pathology*
  • Female
  • Gastrointestinal Hemorrhage / etiology*
  • Humans
  • Jejunal Neoplasms / complications
  • Jejunal Neoplasms / drug therapy*
  • Jejunal Neoplasms / pathology*
  • Lymphoma, Follicular / complications
  • Lymphoma, Follicular / drug therapy*
  • Male
  • Middle Aged
  • Remission Induction
  • Rituximab / therapeutic use

Substances

  • Antineoplastic Agents
  • Rituximab